Use and timing of radiotherapy in high-risk prostate cancer

被引：2
|
作者：
Ward, JF [1 ]
Blute, ML
机构：
[1] USN, Dept Urol Oncol, Med Ctr, Portsmouth, VA 23708 USA
[2] Mayo Clin, Dept Urol, Rochester, MN USA
来源：
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2004年 / 291卷 / 23期
关键词：
D O I：
10.1001/jama.291.23.2817-a
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：2817 / 2817
页数：1
相关论文
共 50 条
  • [41] Safety and Efficacy of Neoadjuvant Docetaxel and Radiotherapy in Localized High-Risk Prostate Cancer
    Ohaegbulam, Kim C.
    Post, Carl M.
    Farris, Paige E.
    Garzotto, Mark
    Beer, Tomasz M.
    Hung, Arthur
    Williamson, Casey W.
    AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS, 2025, 48 (02): : 75 - 82
  • [42] Dose escalation of external beam radiotherapy for high-risk prostate cancer-Impact of multiple high-risk factor
    Umezawa, Rei
    Inaba, Koji
    Nakamura, Satoshi
    Wakita, Akihisa
    Okamoto, Hiroyuki
    Tsuchida, Keisuke
    Kashihara, Tairo
    Kobayashi, Kazuma
    Harada, Ken
    Takahashi, Kana
    Murakami, Naoya
    Ito, Yoshinori
    Igaki, Hiroshi
    Jingu, Keiichi
    Itami, Jun
    ASIAN JOURNAL OF UROLOGY, 2019, 6 (02) : 192 - 199
  • [43] Classifying high-risk versus very high-risk prostate cancer: is it relevant to outcomes of conformal radiotherapy and androgen deprivation?
    Akram Saad
    Jeffrey Goldstein
    Yaacov R. Lawrence
    Benjamin Spieler
    Raya Leibowitz-Amit
    Raanan Berger
    Tima Davidson
    Damien Urban
    Lev Tsang
    Dror Alezra
    Ilana Weiss
    Zvi Symon
    Radiation Oncology, 12
  • [44] Stereotactic Ablative Body Radiotherapy for Intermediate- or High-Risk Prostate Cancer
    Loblaw, Andrew
    CANCER JOURNAL, 2020, 26 (01): : 38 - 42
  • [45] Dosimetric Comparison and Toxicity Analysis of Stereotactic Radiotherapy for High-Risk Prostate Cancer
    Callan, L.
    Bauman, G. S.
    Chen, J.
    Lock, M. I.
    Sexton, T. L.
    D'Souza, D. P.
    Rodrigues, G.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2019, 105 (01): : E268 - E269
  • [46] Timing of biochemical failure and distant metastatic disease for low-, intermediate-, and high-risk prostate cancer after radiotherapy
    Morgan, Peter B.
    Hanlon, Alexandra L.
    Horwitz, Eric M.
    Buyyounouski, Mark K.
    Uzzo, Robert G.
    Pollack, Alan
    CANCER, 2007, 110 (01) : 68 - 80
  • [47] Impact of timing of adjuvant radiotherapy on locoregional control in patients with high-risk endometrial cancer
    Diaz-cazares, Omar
    Olimon, Cipatli
    Valles, Adrian
    Sanchez, Irving
    Balderrama, Ricardo
    Fuentes, Jesus
    Rodriguez, Jose
    Saavedra, Carlos
    Ayala-Hernandez, Luis E.
    Villalvazo-Anaya, Alejandro
    Mireles-Ramirez, Mario A.
    Chavez, Allan Hernandez
    Bayardo, Luis H.
    Gutierrez-Valencia, Enrique
    JOURNAL OF CANCER METASTASIS AND TREATMENT, 2023, 9
  • [48] Postoperative irradiation combined with chemotherapy for high-risk rectal cancer patients: The timing of radiotherapy
    Merimsky, O
    Kovner, F
    Chaitchik, S
    Inbar, M
    ONCOLOGY REPORTS, 1997, 4 (05) : 1093 - 1097
  • [49] Optimal timing of radiotherapy in high risk prostate cancer: Do missed days matter?
    Hasan, Shaakir
    Gorovets, Daniel
    Lehrer, Eric J.
    Lazarev, Stanislav
    Press, Robert H.
    Garg, Madhur
    Mehta, Keyur J.
    Chhabra, Arpit M.
    Choi, J. Isabelle
    Simone, Charles B., II
    CLINICAL AND TRANSLATIONAL RADIATION ONCOLOGY, 2021, 26 : 47 - 54
  • [50] Postmastectomy radiotherapy use in elderly patients with high-risk breast cancer
    Lee, J
    Truong, P
    Kader, H
    Speers, C
    Olivotto, I
    RADIOTHERAPY AND ONCOLOGY, 2005, 76 : S1 - S1
12345